-
Je něco špatně v tomto záznamu ?
Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors
J. Cardinale, M. Roscher, M. Schäfer, M. Geerlings, M. Benešová, U. Bauder-Wüst, Y. Remde, M. Eder, Z. Nováková, L. Motlová, C. Barinka, FL. Giesel, K. Kopka
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antigeny povrchové MeSH
- glutamátkarboxypeptidasa II antagonisté a inhibitory MeSH
- lidé MeSH
- ligandy MeSH
- nádory prostaty diagnostické zobrazování MeSH
- niacinamid analogy a deriváty chemie farmakologie MeSH
- oligopeptidy chemie farmakologie MeSH
- pozitronová emisní tomografie MeSH
- radiofarmaka farmakologie MeSH
- radioizotopy fluoru chemie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [18F]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012043
- 003
- CZ-PrNML
- 005
- 20210507103241.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.9b01479 $2 doi
- 035 __
- $a (PubMed)32852205
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cardinale, Jens $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 245 10
- $a Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors / $c J. Cardinale, M. Roscher, M. Schäfer, M. Geerlings, M. Benešová, U. Bauder-Wüst, Y. Remde, M. Eder, Z. Nováková, L. Motlová, C. Barinka, FL. Giesel, K. Kopka
- 520 9_
- $a In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [18F]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.
- 650 _2
- $a antigeny povrchové $7 D000954
- 650 _2
- $a radioizotopy fluoru $x chemie $7 D005462
- 650 _2
- $a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $7 D043425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a niacinamid $x analogy a deriváty $x chemie $x farmakologie $7 D009536
- 650 _2
- $a oligopeptidy $x chemie $x farmakologie $7 D009842
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a nádory prostaty $x diagnostické zobrazování $7 D011471
- 650 _2
- $a radiofarmaka $x farmakologie $7 D019275
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Roscher, Mareike $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Schäfer, Martin $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Geerlings, Max $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Benešová, Martina $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Bauder-Wüst, Ulrike $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Remde, Yvonne $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Eder, Matthias $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany
- 700 1_
- $a Nováková, Zora $u Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic
- 700 1_
- $a Motlová, Lucia $u Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic
- 700 1_
- $a Barinka, Cyril $u Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic
- 700 1_
- $a Giesel, Frederik L $u Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany
- 700 1_
- $a Kopka, Klaus $u Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 63, č. 19 (2020), s. 10897-10907
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32852205 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507103240 $b ABA008
- 999 __
- $a ok $b bmc $g 1650427 $s 1132422
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 63 $c 19 $d 10897-10907 $e 20200922 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20210420